The Wilson laboratory is developing metabolism-targeted methods to identify tumors harboring IDHm, either (1) based on consumption of tumor-relevant metabolites or (2) direct detection of the IDHm enzyme via modification of known inhibitor structures. These tools will significantly impact the diagnosis and treatment of low-grade glioma and other lesions. These studies are performed in collaboration with the laboratory of Dr. Pavithra Viswanath and clinical collaborator Dr. Javier Villanueva-Meyer.
